Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA reviewers back Bayer's riociguat with modified dosing

FDA reviewers recommended approval of Adempas riociguat from Bayer AG (Xetra:BAYN) to treat pulmonary arterial hypertension (PAH) and

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE